Kornimate/medical-research-clean huggingface dataset:
a trial comparing mechanical diagnosis and treatment to manual therapy

Conditions: Chronic Lower Back Pain

Summary: mechanical diagnosis and treatment (mdt) and manual therapy (mt) have both demonstrated efficacy in the management of clbp. the use of a point of care (poc) design in this study will allow for comparison of these two treatment modalities in a clinical setting. the purpose of this study is to demonstrate the feasibility of recruiting, enrolling and collecting outcome data on clbp patients utilizing the poc methodology.

20 new patients entering the chiropractic clinic who meet inclusion criteria including demonstrating a directional preference upon physical examination during their initial evaluation will be recruited. patients will be queried as to interest and those interested will be consented. patients will then be randomized utilizing a computer generated randomization chart to receive either mdt or mt delivered in a pragmatic manner. outcomes will include: pain (peg), quality of life (promis global health survey (ghs)), psychosocial questions and self efficacy (2 question). outcomes will be collected at baseline, 4 weeks and 8 weeks post baseline.

Eligibility criteria:
inclusion criteria: * chronic lower back pain (clbp) (\>12 weeks) * veteran * at least 18 years of age * directional preference on physical examination exclusion criteria: * non veteran * \>89 years of age * non mechanical cause of lbp * unable to identify directional preference on physical examination * contraindications to manual therapy (cauda equina syndrome, spinal neoplasia or metastatic disease, destructive joint pathology such as rheumatoid arthritis, bowel/bladder dysfunction (associated with the back pain), peripheral neuropathy or progressive lumbosacral radiculopathy, progressive myelopathy or neurogenic claudication or any absolute contraindications to mt such as acute fracture of the lumbar spine) * open worker's compensation case

Keywords: chronic lower back pain manual therapy mechanical diagnosis and treatment
a multicentre, prospective, single-arm, non-interventional regulatory post-marketing surveillance (rpms) study to investigate the safety and effectiveness of wegovy® (semaglutide) in patients with obesity and patients with overweight in routine clinical practice in korea

Conditions: Obesity and Overweight

Summary: this study is conducted to investigate the safety and effectiveness of semaglutide in participants with obesity and overweight in routine clinical practice. participants will get semaglutide as prescribed by a doctor. this study will last for about 4 years and participants will participate in the study for approximately 26 weeks.


Eligibility criteria:
inclusion criteria: 1. signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. the decision to initiate treatment with commercially available semaglutide has been made by the participants and the treating physician before and independently from the decision to include the participant in this study. 3. male or female adults, age above or equal to 19 years who is scheduled to start treatment with semaglutide based on the clinical judgment of their treating physician as specified in the korean-prescribing information (approved label in korea) at the time of signing informed consent. exclusion criteria: 1. participants who are or have previously been on semaglutide therapy before enrollment. 2. known or suspected hypersensitivity to the active substance or any of the excipients of semaglutide. 3. previous participation in this study. participation is defined as having given informed consent in this study. 4. female participant who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice). 5. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
trial on metoclopramide and ketoprofen in acute migraine of childhood

Conditions: Migraine

Summary: this is a randomized double blind trial with the aim to estimate the effectiveness of 3 therapeutic regimes per os on migraine pain: * metoclopramide 0,15 mg/kg + placebo * metoclopramide 0,15 mg/kg + ketoprofen 1 mg/kg * ketoprofen 1 mg/kg + placebo intensity of pain will be measured with linear 1-10 scale or analogic mcgrath type scale every 20 min. the main objective is the evaluation of healing times from pain in the 3 groups


Eligibility criteria:
inclusion criteria: * children 6-17 years old with migraine presenting in emergency room exclusion criteria: * informed consensus not obtained * occurring migraine still treated * hemiplegic migraine

Keywords: migraine metoclopramide ketoprofen child
evaluation of antithrombin deficiency in patients of intensive care unit placed on extracorporeal membrane oxygenation

Conditions: Severe Cardiac Insufficiency

Summary: prospective, monocentric, non-interventional study in patients placed on extracorporeal membrane oxygenation (ecmo)

our hypothesis is that ecmo initiation is responsible for a severe decrease of antithrombin level in a high proportion of patients who develop heparin resistance.

Eligibility criteria:
inclusion criteria: * any icu patient of receiving veno-arterial extracorporeal membrane oxygenation * patients who have not expressed opposition to participate exclusion criteria: * arterial thrombosis or progressive venous thrombosis * contraindication to heparin * constitutional deficiency in antithrombin * patient refusal * minor patient * protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty

Keywords: extracorporeal membrane oxygenation
immediate implant placement with different materials of customized healing abutment for guiding peri-implant soft tissue healing in posterior teeth

Conditions: Peri-implant Mucositis

Summary: : immediate implant placement with different materials of customized healing abutment for guiding peri-implant soft tissue healing in posterior teeth: a randomized controlled clinical trial.

this randomized clinical trial evaluates the effect of customized peek healing abutment versus composite healing abutment regarding clinical evaluation 1. gingival margin distance 2. gingival margin height 3. gingival contour width 4. gingival volume in bl \& md aspects on guiding the peri- implant soft tissue emergency profile in posterior teeth after immediate implant placement

Eligibility criteria:
inclusion criteria: * inclusion criteria of participants: * periodontally and systemic healthy patients * patients aged \> 18 years * non- restored teeth for many reasons (i.e. endodontic failure, unworthy for treatment in deep caries/non-caries lesion and root fracture), locate in the posterior area in the maxillary or mandibular arch indicate for customized implant with no need for additional bone and soft tissue augmentation procedures. * an adequate vertical bone for immediate implant placement. * implants will be positioned with adequate primary stability so that transmucosal healing can be accomplished. * no taken medications known to interfere healing or periodontal tissue health or bone metabolism. * no previous periodontal surgery at involved sites. * good oral hygiene and good compliance with the plaque control instructions following initial therapy. exclusion criteria: * patients with active periodontal diseases (bleeding on probing- probing depth \> 4 mm) or those under orthodontic treatment. * poor oral hygiene (full mouth plaque score \> 25% and full mouth bleeding score \> 25%) * smoking habits (\> 10 cigarettes/day) * severe acute or chronic periodontitis * severe bruxism habits * history of oral/iv bisphosphonates taking * remote or recent radiation therapy in the oro-maxillo-facial area or recent chemotherapy. * xerostomia * pregnant and lactating mothers * patients who have been received periodontal surgery in the study area during the last year. * clinical or radiographic signs of periapical pathology contraindicating immediate implant placement. * implants showing signs of peri-implant mucositis and peri-implantitis during the study period will be excluded from the following analyses.
pregnancies and cystic fibrosis

Conditions: Cystic Fibrosis

Summary: there have been substantial advances in care for individuals with cf, including improved nutrition and respiratory care. women with cf are now likely to survive into adulthood with a median predicted survival of 49.7 years in 2012, which have resulted in increasingly normal lifestyles, including successful pregnancies in women with cf. the number of pregnancies in cf women has increased as reported by the 2013 annual data report from the french cf registry (6 pregnancies in 1992 to 53 in 2012). pregnancy adds many physiological stresses to the body, particularly on pulmonary function (decrease in residual volume, expiratory reserve capacity) and nutritional status (increase in nutritional needs). in women with cf, these added stresses could theoretically affect survival, with difficulties to maintain adequate nutrition and an unpredictable effect on lung function. a number of studies published over the past 15 years have attempted to clarify the risk of pregnancy in women with cf to guide clinicians and women. many authors compared the outcomes of pregnant cf women to non-pregnant cf women regardless of nutritional status, lung function, diabetes mellitus, bacteriological colonization. in literature, pregnancy was possible and well tolerated in cf women with mild disease if associated with more intensive monitoring and aggressive treatment during pregnancy, with particular emphasis on nutrition and weight gain. cf women have an increased likelihood of receiving treatment for diabetes both during and after pregnancy. furthermore diabetes mellitus has been associated with more severe pulmonary disease, more frequent pulmonary exacerbations, poorer nutritional status and a reduced life expectancy. pre-pregnancy diabetes mellitus is associated with a poorer prognosis for pregnancy in general population. severe forms of cf, including pre-pregnancy diabetes mellitus might as well do badly with accelerated decline after pregnancy. to determine the effect of pre-pregnancy diabetes on maternal decline after pregnancy, we will compare fev1 and bmi rates of decline, during a two-years follow-up period after pregnancies, reported in the french cf registry, according to their diabetic status.


Eligibility criteria:
inclusion criteria: * cystic fibrosis women attending the cf french registry between january 1, 2001 and december 31, 2010 exclusion criteria: * women who had received a pulmonary graft before pregnancy.

Keywords: cystic fibrosis - pregnancy - diabetes
mechanisms of acute kidney injury in severe infections

Conditions: Sepsis; AKI - Acute Kidney Injury; Positron Emission Tomography (PET)

Summary: renal perfusion and neutrophil-mediated inflammation will be assessed in the kidney in sepsis patients with acute kidney injury using positron emission tomography. for marked water will be used for renal perfusion and a newly developed pet tracer molecule (11c-gw457427) with specific binding to neutrophil elastase which provides a measure of the amount of infiltrating neutrophils in the renal parenchyma for inflammation. the study is performed in a pet-ct camera where anatomical imaging takes place at the same time as the pet examinations.

to study renal perfusion and neutrophil-mediated inflammation 10 critically ill patients with sepsis and acute kidney injury (aki) and 5 healthy volunteers as controls will be recruited and examined at one time with marked water followed by neutrophil elastase tracer. at the same time, a ct scan is performed for anatomy. plasma levels of inflammatory mediators will be measured. clinical data will be collected. the endpoints are changes in renal perfusion and increased presence of neutrophil elastase in the renal parenchyma.

Eligibility criteria:
inclusion criteria: patients with sepsis and aki * \> 30 years * at least aki stage 1 according to kdigo where the last plasma creatinine is measured within 24 hours of the examination healthy volunteers * \> 30 years * no previously known kidney disease * normal plasma creatinine value exclusion criteria: * chronic renal failure (ckd stage \>3a) or dialysis * instability in vital functions that makes pet-ct examination unsuitable * claustrophobia or other reasons that make the patient unable to lie still during the examination. * pregnancy and breastfeeding
long-term safety study of kineret® in patients with systemic juvenile idiopathic arthritis (sjia)

Conditions: Still Disease, Juvenile Onset

Summary: the purpose of the study is to evaluate and characterize long-term safety of kineret when used in standard clinical practice to treat patients with systemic juvenile idiopathic arthritis (sjia). the study will be based on already available data from the pharmachild juvenile idiopathic arthritis (jia) registry which holds the european network of centers for pharmacoepidemiology and pharmacovigilance (encepp) study seal.

this is an international, non-interventional, single-armed, pharmacovigilance registry study on long-term safety of kineret utilizing already available data from the encepp certified pharmachild jia registry. the paediatric rheumatology international trials organisation (printo) is a non-profit, non-governmental, international research network with the goal to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centers, international clinical trials and/or outcome standardization studies in children with paediatric rheumatic diseases. the pharmachild jia registry, maintained by printo, is a registry collecting data from patients with jia including patients with sjia. in the pharmachild jia registry 40 countries are participating of which 15 countries have collected data on kineret treatment. this study includes secondary use of data already available in the pharmachild jia registry.

Eligibility criteria:
inclusion criteria: * male and female patients with a diagnosis of sjia as per the international league of associations for rheumatology (ilar) classification criteria * included in the pharmachild registry * ever treated with kineret subsequently to sjia diagnosis exclusion criteria: no specific exclusion criteria will be applied.

Keywords: sjia kineret anakinra long term safety
robohear™ device: advanced haptic technology that allows the deaf to understand speech

Conditions: Hearing Impairment; Deafness

Summary: pilot study to test the feasibility of translating the english language into haptics (touch sensations)

an adaptive pilot trial of robohear™ hardware and software to test the feasibility of learning to understand language using a haptic (touch) device installed in the stem of a pair of glasses. these tests are not meant to be exhaustive but will validate the hardware and software and provide an informal test platform for learning to 'hear' or interpret sounds and words using haptic technology.

Eligibility criteria:
inclusion criteria: * participants need to understand english. * participants must be able to sit at a computer for the training and evaluation session. the session may range from one hour to up to 4 hours in length (with breaks provided as needed). exclusion criteria: * inability to understand english
muscle metabolism and oxygenation during localized fatigue-exercise in copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this study is to investigate whether a localized exercise, in which cardiorespiratory demand is reduced, will result in greater limb muscle fatigue in patients with copd as a consequence of muscle oxygenation and muscle metabolism disturbances.


Eligibility criteria:
inclusion criteria: * copd (fev1/fvc \< 0.70 and fev1 \< 0.80 predicted * healthy subjects: no evidence of airways obstruction (fev1/fvc \> 0.70 and fev1 \> 0.80 predicted) * smoking history \> 15 pack-years exclusion criteria: * chronic hypoxemia and/or hypercapnia (pao2 \ 45 mmhg) * recent exacerbation (\< 3 months) * recent cancer (\< 3 years) * diabetes * myopathy, neuromuscular or articular disease * unstable cardiac disease * absolute contraindications to exercise testing * regular physical activity or exercise training program in the last 2 months * physical activity score \> 9 in the voorips questionnaire * thigh skinfold thickness \> 15 mm * bmi \> 30

Keywords: pulmonary disease, chronic obstructive muscle fatigue energy metabolism muscle oxygenation
from research to practice - lipid management for low hdl-cholesterol

Conditions: Physicians' Practice Patterns; Coronary Heart Disease

Summary: the overall purpose of this project is to improve the clinical outcomes of veterans with ischemic heart disease (ihd) through implementation of evidence-based lipid management, with a particular focus on veterans whose primary lipid abnormality is a low level of hdl-cholesterol (the �good� cholesterol).

background: the overall purpose of this project is to improve the clinical outcomes of veterans with ischemic heart disease (ihd) through implementation of evidence-based lipid management, with a particular focus on veterans whose primary lipid abnormality is a low level of hdl-cholesterol (the �good� cholesterol). objectives: the major objectives are 1. to determine whether a multifaceted intervention results in improved guideline-concordant lipid management for patients with low hdl-cholesterol; and 2. to test the relative effectiveness of three different reminder systems on physician prescribing behavior. methods: the primary care clinic at each of the six visn 13 facilities will serve as intervention sites. within those sites we will randomize providers to one of three reminder systems. control sites will consist of twelve other facilities matched to the intervention sites on the basis of facility characteristics. we will use a modified �pre-post� nested cohort design that allows us to evaluate the effect of the intervention controlling for secular trends. target patients will be identified based on the following: 1. an ihd diagnosis within the past 5 years; 2. regular follow-up in a primary care clinic; 3. most recent ldl-cholesterol \< 130 mg/dl and hdl-cholesterol \< 40 mg/dl; 4. no lipid therapy within prior 6 months. the intervention will consist of: a. an on-site interactive educational workshop for providers; b. reminders (either patient-directed mailed reminders, computer-chart reminders at the time of visit, or automatic consults); c. opinion leader recruitment and �activation�. the primary outcome is proportion of target patients receiving guideline-concordant therapy. for objective 1, the outcome will be compared between intervention and control sites. for objective 2, the outcome will be compared between the three groups randomized to the different reminder systems. in addition, providers will be surveyed with a written questionnaire to determine their reaction to the educational workshop and the different reminder systems. status: intervention and data collection are completed. data analysis is being undertaken, final report will soon follow.

Eligibility criteria:
inclusion criteria: subjects are primary care providers from participating visn sites. patients whose medical records are utilized are selected via an algorithm. exclusion criteria:
optimisation of high flow oxygen therapy settings during hypoxaemic respiratory distress based on non-contact measurement of lung volumes by depth camera

Conditions: Hypoxemic Respiratory Failure

Summary: the goal of this clinical trial is to validate the interest of a strategy adjusting the flow rate delivered under high-flow oxygen (hfo) therapy according to the lung volumes measured by a new technique, in intensive care patients with hypoxemic respiratory distress (hrd). the main question it aims to answer is: "the use of a technique of measurement of lung pulmonary with adjustement to the flow rate can make it possible to limite intubation in patients with hrd in intensive care?" the participants will be the patients admitted in intensive care for hrd with the need for treatment with hfo. this participants will be randomized in : * the arm control: treated by high flow oxygen therapy according to standard procedures. * or in the experimental arm : treated by high flow oxygen therapy with adjustement of ventilatory parametres based on lung volume measurements, obtained by the depth camera.

high-flow oxygen therapy (hfo) is a common technique for the management of patient with hypoxemic respiratory distress in intensive care.the variations in lung volumes induced by the hfo in patients is unknown in clinical routine, in the absence of the availability of a effective measurement technique. the investigators research team validated a new non-invasive, non-contact technique for measuring lung volumes using depth camera. using a stereoscopic camera, the patient's chest and abdomen are recognized by a artificial intelligence algorithms. the structures of interest of the chest and the abdomen are the identified and the variation in depth of these points in space allows both the integration of lung volume through automatic calibration procedures, the measurement of respiratory rate and comparaison of movement symetries.

Eligibility criteria:
inclusion criteria: * patients with hypoxemic respiratory distress define by the following 4 criteria: * respiratory rate ≥ 25 breaths per minutes * a ratio of the partial pressure of arterial oxygen (pao2) to the fio2 ≤ 300 mmhg while the patient is breathing oxygen at a flow rate of 10 liters per minutes or more * a partial pressure of arterial carbon dioxide (paco2) not higher than 45 mmhg * an absence of clinical history of underlying chronic respiratory failure exclusion criteria: * a do-not-intubate order * pregnant or lactating woman * cardiogenic pulmonary edema * exacerbation of asthma * hemodynamic instability with use of vasopressor at significant dose (norepinephrine \> 0.5 mg/h) * a glasgow coma scale of 12 points of less * contraindications to non-invasive ventilation * urgent need for endotracheal intubation * high flow oxygen therapy started within 48 hours before inclusion * patient under legal protection or deprived of liberty

Keywords: flow oxygen lung volume depth camera